(Reuters) – U.S. Department of Health and Human Services on Friday signed an agreement with AstraZeneca Plc for development and supply of the company’s COVID-19 antibody treatment, a cocktail of two monoclonal antibodies – similar class of drugs that was administered to President Donald Trump.
The agency will provide nearly $486 million to AstraZeneca for two Phase 3 clinical trials as well as a large-scale manufacturing demonstration project and supply of AZD7442 doses in the United States.
(Reporting by Ankur Banerjee in Bengaluru; Editing by Anil D’Silva)
